Your analysis makes good sense with clear rationality. In particular, the impact of GLP-1s on Obstructive Sleep Apnea (OSA) and subsequently on ResMed’s volumes is a core uncertainty for the years ahead. However, I remain confident that there are much more penetrations of continuous positive airway pressure (CPAP) therapy to people in developed and developing countries in particular.
Having noted the impact of GLP-1s on RMD share price, the price goes up and up as we are worrying and writing.
Looking at RSI (14 & 30 days line) technical indications, it is not in overbought territory yet.
Buy RMD now and get great upside returns in a year or two, page-62
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.95 |
Change
0.170(0.53%) |
Mkt cap ! $20.28B | |||
| Open | High | Low | Value | Volume |
| $31.78 | $31.95 | $31.72 | $23.42M | 734.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 601 | $31.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.96 | 31160 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$31.92 |
Change
0.170 ( 0.61 %) |
||||
| Open | High | Low | Volume | ||
| $31.77 | $31.95 | $31.72 | 189067 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| RMD (ASX) Chart |